Patents Assigned to Takeda Pharmaceutical Company Limited
  • Publication number: 20240124593
    Abstract: The disclosure relates to antibodies that bind FcRn and methods of using these antibodies.
    Type: Application
    Filed: July 6, 2023
    Publication date: April 18, 2024
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Christopher TenHoor, Malini Viswanathan
  • Publication number: 20240125767
    Abstract: The present invention provides drug toxicity evaluation platforms (such as an evaluation method and a kit therefor) that enable detailed analysis of the possibility and the like of developing drug-induced damage (such as DILI) to the liver and other organs. The method for evaluating drug toxicity of the present invention includes: a step of adding a drug to a co-culture system of an organoid and blood cells; and a step of evaluating the toxicity of the drug to the organoid.
    Type: Application
    Filed: October 16, 2020
    Publication date: April 18, 2024
    Applicants: Public University Corporation Yokohama City University, Takeda Pharmaceutical Company Limited
    Inventors: Takanori TAKEBE, Norikazu SAIKI
  • Patent number: 11959100
    Abstract: As a technique for proliferating neural crest cells without reducing differentiation capacity, provided is a method for producing neural crest cells, comprising the steps of: (1) obtaining neural crest cells; and (2) suspension-culturing the neural crest cells in a medium comprising a GSK3? inhibitor and a basic fibroblast growth factor (bFGF), wherein the medium comprises the GSK3? inhibitor with a concentration that exhibits an effect equivalent to that exhibited by CHIR99021 with a concentration of higher than 1 ?M and lower than 5 ?M.
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: April 16, 2024
    Assignees: Kyoto University, Takeda Pharmaceutical Company Limited
    Inventors: Makoto Ikeya, Yayoi Kamiya
  • Patent number: 11957684
    Abstract: Methods for treating uterine fibroids, endometriosis, adenomyosis, or heavy menstrual bleeding in a subject, which include administering to the subject from 10 mg to 60 mg per day of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N?-methoxyurea, and from 0.01 mg to 5 mg per day of a hormone replacement medicament. The present disclosure has methods for reducing menstrual bleeding in a subject, reducing bone mineral density loss in a subject caused by administering a GnRH antagonist to the subject, suppressing sex hormones in a subject, reducing vasomotor symptoms or hot flashes in a subject, and reducing symptoms of decreased libido in a subject having uterine fibroids, endometriosis, or adenomyosis.
    Type: Grant
    Filed: July 15, 2022
    Date of Patent: April 16, 2024
    Assignees: Sumitomo Pharma Switzerland GmbH, Takeda Pharmaceutical Company Limited
    Inventors: Brendan Mark Johnson, Lynn Seely, Paul N. Mudd, Jr., Susan Wollowitz, Mark Hibberd, Masataka Tanimoto, Vijaykumar Reddy Rajasekhar, Mayukh Vasant Sukhatme
  • Patent number: 11958845
    Abstract: The present invention provides a heterocyclic compound having a HDAC6 inhibitory action, which is useful for the treatment of central nervous system diseases including neurodegenerative diseases, and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.
    Type: Grant
    Filed: September 26, 2022
    Date of Patent: April 16, 2024
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Masahiro Ito, Hideyuki Sugiyama, Takeshi Yamamoto, Keiko Kakegawa, Jinxing Li, Junsi Wang, Takahito Kasahara, Masato Yoshikawa
  • Patent number: 11957867
    Abstract: A syringe stabilizing apparatus has a base and a syringe support. The syringe support is vertically disposed above the base, elevating a fluid-filled portion of an infusion set vertically above the base and orienting a delivery end of the fluid-filled portion upwardly relative to a horizontal plane to take advantage of a gravitational effect on a fluid during delivery of the fluid from the fluid-filled portion to a patient. The syringe support comprises a first retainer and a selectively actuated tube clamp. The first retainer has an opening in which a rigid portion of the infusion set is received and retained therein without further user intervention. The selectively actuated tube clamp is operatively aligned with the first retainer. A flexible tube extending from the rigid portion of the infusion set extends through the selectively actuated tube clamp.
    Type: Grant
    Filed: June 26, 2017
    Date of Patent: April 16, 2024
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Scott Richard Ariagno, Angela Teresa Muriset, Daniel Edward Roush, Denise A. Alexander, Madeleine Clare Gibson, Gin-Fu Chen
  • Patent number: 11958850
    Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including mutant EGFR and mutant HER2 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including mutant EGFR and mutant HER2 activity, are described herein.
    Type: Grant
    Filed: August 31, 2021
    Date of Patent: April 16, 2024
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Wei-Sheng Huang, Yongjin Gong, Feng Li, Nicholas E. Bencivenga, David C. Dalgarno, Anna Kohlmann, William C. Shakespeare, Ranny M. Thomas, Xiaotian Zhu, Angela V. West, Willmen Youngsaye, Yun Zhang, Tianjun Zhou
  • Publication number: 20240117346
    Abstract: In an embodiment, an object of the present invention is to provide a double-stranded nucleic acid complex having a novel structure. In an embodiment, the present invention relates to a nucleic acid complex comprising a first nucleic acid strand and a second nucleic acid strand, wherein said first nucleic acid strand: (1) is capable of hybridizing to at least a part of a target transcriptional product; (2) has an antisense effect on the target transcriptional product; and (3) is a gapmer comprising a central region, and a 5? wing region and a 3? wing region, said second nucleic acid strand comprises at least one sugar-unmodified central region (first exposed region) consisting of one sugar-unmodified ribonucleoside or two or three contiguous sugar-unmodified ribonucleosides linked by an internucleoside bond, which is or are complementary to a part of said first nucleic acid strand, and said first nucleic acid strand is annealed to said second nucleic acid strand.
    Type: Application
    Filed: October 9, 2020
    Publication date: April 11, 2024
    Applicants: National University Corporation Tokyo Medical and Dental University, Takeda Pharmaceutical Company Limited
    Inventors: Takanori Yokota, Tetsuya Nagata, Hiroki Yamada, Hideki Furukawa, Takatoshi Yogo, Kenichi Miyata, Akio Uchida, Naoki Tomita
  • Patent number: 11952344
    Abstract: Provided is a heterocyclic compound that can have an antagonistic action on an NMD A receptor containing the NR2B subunit and that is expected to be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I), wherein each symbol is as defined in the DESCRIPTION, or a salt thereof.
    Type: Grant
    Filed: September 25, 2020
    Date of Patent: April 9, 2024
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Yuya Oguro, Makoto Kamata, Shuhei Ikeda, Takeshi Wakabayashi, Norihito Tokunaga, Taku Kamei, Mitsuhiro Ito, Shigemitsu Matsumoto, Hirotaka Kamitani, Takaharu Hirayama, Toshio Tanaka, Hiroshi Banno, Nobuyuki Takakura, Jinichi Yonemori, Takuya Fujimoto
  • Patent number: 11938174
    Abstract: Compositions and methods useful for the treatment of neuromyelitis optica (NMO) or neuromyelitis optica spectrum disorder (NMOSD) are disclosed.
    Type: Grant
    Filed: September 11, 2020
    Date of Patent: March 26, 2024
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Colin Broom, Jeffrey Dayno
  • Patent number: 11939327
    Abstract: The present invention aims to provide a heterocyclic compound having an AMPA receptor potentiator effect, which is expected to be useful as an agent for the prophylaxis or treatment of depression, Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.
    Type: Grant
    Filed: August 15, 2022
    Date of Patent: March 26, 2024
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Tomoaki Hasui, Shinji Nakamura, Satoshi Mikami, Tohru Yamashita
  • Publication number: 20240091414
    Abstract: The invention provides, inter cilia, ultra-thin conformal coated biological surfaces, such as living cells, cell clusters, tissues, organs, and hybrid synthetic organs, and methods of making the same, e.g., using click reactive water soluble polymers, under conditions that do not damage or significantly modify the biological surfaces. In some embodiments, the coated biological surfaces are suitable for delivery to a subject in need thereof.
    Type: Application
    Filed: July 19, 2023
    Publication date: March 21, 2024
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Venkata R. Garigapati, Tetsuya Matsuura
  • Publication number: 20240082479
    Abstract: Containers for one or more fluid delivery systems are disclosed.
    Type: Application
    Filed: November 22, 2021
    Publication date: March 14, 2024
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Jeffrey PELTIER, Peter MURPHY, Eugene CANAVAN
  • Publication number: 20240082493
    Abstract: Fluid delivery devices for delivering therapeutic agents are described. More particularly, this disclosure relates to drug reconstitution devices having a plurality of components movable with respect to one another such that an active agent and a solvent can be reconstituted within the device prior to injection. The fluid delivery devices can include a housing, a cartridge holder, a cartridge disposed within the cartridge holder, a button rod, and a foot. The cartridge stores the active agent and the solvent, which are separated by one or more stoppers. The button rod and foot can provide an axial force upon the stopper(s) in the cartridge to inject the fluid once reconstituted. The foot and the button rod can be separate components, thereby enabling the foot to rotate independently with respect to the button rod as the cartridge holder is rotated to reconstitute the therapeutic and prime the device for injection.
    Type: Application
    Filed: November 22, 2021
    Publication date: March 14, 2024
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Shekhar NIMKAR, Arnaz MALHI, William G. ATTERBURY, Jessica Diane YOUNG, Beverly Anne PIATT, James Alan PRESCOTT, Adam C. FOX
  • Publication number: 20240082111
    Abstract: In some embodiments, a reconstitution or medicinal fluid delivery device includes a transfer engine including two fluidly connected spikes, each configured to pierce a container. A check valve may be disposed between the two spikes to allow unidirectional flow from one container to the other. Physical access to a fluid outlet may be obstructed by a housing until the reconstitution or medicinal fluid delivery device is actuated, whereupon physical access to the fluid outlet is permitted. The reconstitution or medicinal fluid delivery device may be placed on a flat surface and actuated with force applied in a single direction toward the flat surface.
    Type: Application
    Filed: September 21, 2023
    Publication date: March 14, 2024
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Joseph M. Giamo, Thomas Boyajian, Amey Mathakari, Anh Nguyen, Dhairya Kirtikumar Mehta
  • Patent number: 11926926
    Abstract: Provided are compositions and methods for preparing and identifying antibodies having CDR3s that vary in sequence and in length from very short to very long which in certain embodiments may bind to a carbohydrate moiety or the active site of an enzyme. Libraries coding for antibodies with the CDR3s are also provided. The libraries can be provided by modifying a pre-existing nucleic acid library.
    Type: Grant
    Filed: June 9, 2020
    Date of Patent: March 12, 2024
    Assignee: Takeda Pharmaceutical Company Limited
    Inventor: Robert Charles Ladner
  • Patent number: 11921117
    Abstract: The present specification discloses methods of characterizing a population of particles using a particle analyzer. Particles may be characterized by size, absolute number, whether the particle is non-proteinaceous or proteinaceous, whether a proteinaceous particle has or lacks a certain physical property, or any combination thereof.
    Type: Grant
    Filed: March 11, 2019
    Date of Patent: March 5, 2024
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Mantas Malisauskas, Christian Lubich, Thomas Prenninger, Birgit Reipert
  • Patent number: D1018556
    Type: Grant
    Filed: March 31, 2021
    Date of Patent: March 19, 2024
    Assignee: Takeda Pharmaceutical Company Limited
    Inventor: Stefano De Socio
  • Patent number: D1023287
    Type: Grant
    Filed: March 17, 2022
    Date of Patent: April 16, 2024
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: John Kenneth Hainsworth, Matthew John Garwood, Matthew Ian Murchie, Hong Choo Tang, Fabian Ghoshal
  • Patent number: D1023288
    Type: Grant
    Filed: March 17, 2022
    Date of Patent: April 16, 2024
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: John Kenneth Hainsworth, Matthew John Garwood, Matthew Ian Murchie, Hong Choo Tang, Jason Robinson